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A B S T R A C T
Background
The SARS outbreak of 2002–2003 presented clinicians with a new, life-threatening disease for
which they had no experience in treating and no research on the effectiveness of treatment
options. The World Health Organization (WHO) expert panel on SARS treatment requested a
systematic review and comprehensive summary of treatments used for SARS-infected patients
in order to guide future treatment and identify priorities for research.
Methods and Findings
In response to the WHO request we conducted a systematic review of the published
literature on ribavirin, corticosteroids, lopinavir and ritonavir (LPV/r), type I interferon (IFN),
intravenous immunoglobulin (IVIG), and SARS convalescent plasma from both in vitro studies
and in SARS patients. We also searched for clinical trial evidence of treatment for acute
respiratory distress syndrome. Sources of data were the literature databases MEDLINE, EMBASE,
BIOSIS, and the Cochrane Central Register of Controlled Trials (CENTRAL) up to February 2005.
Data from publications were extracted and evidence within studies was classified using
predefined criteria. In total, 54 SARS treatment studies, 15 in vitro studies, and three acute
respiratory distress syndrome studies met our inclusion criteria. Within in vitro studies, ribavirin,
lopinavir, and type I IFN showed inhibition of SARS-CoV in tissue culture. In SARS-infected
patient reports on ribavirin, 26 studies were classified as inconclusive, and four showed possible
harm. Seven studies of convalescent plasma or IVIG, three of IFN type I, and two of LPV/r were
inconclusive. In 29 studies of steroid use, 25 were inconclusive and four were classified as
causing possible harm.
Conclusions
Despite an extensive literature reporting on SARS treatments, it was not possible to
determine whether treatments benefited patients during the SARS outbreak. Some may have
been harmful. Clinical trials should be designed to validate a standard protocol for dosage and
timing, and to accrue data in real time during future outbreaks to monitor specific adverse
effects and help inform treatment.
The Editors’ Summary of this article follows the references.
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Introduction
The severe acute respiratory syndrome (SARS) is a febrile
respiratory illness primarily transmitted by respiratory
droplets or close personal contact. A global outbreak of
SARS between March 2003 and July 2003 caused over 8,000
probable or conﬁrmed cases and 774 deaths [1]. The causative
organism has been identiﬁed as a novel coronavirus (SARS-
CoV) [2–4]. The overall mortality during the outbreak was
estimated at 9.6% [5,6]. The overriding clinical feature of
SARS is the rapidity with which many patients develop
symptoms of acute respiratory distress syndrome (ARDS).
This complication occurred in approximately 16% of all
patients with SARS, and when it occurred was associated with
a mortality rate of 50% [7,8].
At the time of the SARS epidemic it was not known what
treatments would reduce SARS-related illness and deaths.
Because the urgency of the international outbreak did not
allow time for efﬁcacy studies, physicians in Canada and
Hong Kong treated the earliest patients with intravenous
ribavirin, based on its broad-spectrum antiviral activity [9,10].
Corticosteroids and immune-modulating agents were often
prescribed empirically. Soon after SARS-CoV was identiﬁed
as the causative agent, antiviral screening programs were
initiated; these programs reported several antiviral agents
that inhibited SARS-CoV replication in vitro. These results
led to the experimental use of protease inhibitors and
interferon alpha (IFN-a) in the treatment of patients.
The most commonly used treatments for SARS are
associated with adverse effects when used for other con-
ditions (Table S1). In October 2003, the WHO established an
International SARS Treatment Study Group, consisting of
experts experienced in managing SARS. The group recom-
mended a systematic review of potential treatment options to
identify the targets for proper evaluation in trials should the
disease recur [11]. This paper reports on this systematic
review designed to summarise available evidence on the
effects of ribavirin, lopinavir and ritonavir (LPV/r), cortico-
steroids, type I IFN, intravenous immunoglobulin (IVIG), or
convalescent plasma in relation to (1) SARS-CoV replication
inhibition in vitro; (2) mortality or morbidity in SARS
patients; and (3) effects on ARDS in adult patients.
Methods
We prepared a protocol that deﬁned our scope, inclusion
criteria, and outcomes to be assessed. The interventions we
included were deﬁned by the WHO: ribavirin, LPV/r, cortico-
steroids, type I IFN, convalescent plasma, or IVIG.
The types of study we included were: (1) in vitro studies, in
which the authors examined inhibition of SARS-CoV viral
replication, and data from an assay in human or animal cell
line; (2) in vivo studies, which included randomised con-
trolled trial (RCT), or prospective uncontrolled study design,
or retrospective cohort design, or case-control design, or a case
series, and patients treated for SARS, and ten or more
patients; and (3) studies of ARDS that included RCT, or
systematic review, and treatment for ARDS or acute lung
injury, and 20 or more patients. In February 2005, we
systematically searched the literature databases MEDLINE,
EMBASE, BIOSIS, and the Cochrane Central Register of
Controlled Trials (CENTRAL) for articles that included the
selected treatments (Table S2).
The full text of each identiﬁed study was retrieved and each
was independently reviewed by two authors (LS and RB).
Publications in Chinese were selected after review of the
English abstract. Unpublished data were not sought, as the
task of summarising existing published data was extensive
and the International SARS Treatment Group indicated that
much of the clinical data had already been published. We
used the QUOROM checklist to help ensure the quality of this
review (Table S3).
Data from the full text of studies in English were extracted
independently by two authors (LS and RB). Data from the
Chinese literature were extracted with the assistance of a
translator. Because the Chinese articles were reviewed by only
one author, the consistency of the translated information
with that from English articles was maintained by subsequent
discussion with the translator to verify the extracted data.
We established explicit criteria to assess the level of
evidence for each human treatment study (Box 1). Since the
treatments chosen for evaluation were often given in
combination, evidence was classiﬁed by the treatment that
was given to all patients in the cohort or given to some with
the author’s intention of studying its effects. If putative
effects within a study included several drugs, then we
extracted data for each intervention. The level of evidence
was independently classiﬁed by two authors (LS and RB).
Chinese studies were appraised and classiﬁed in the same way
using translated information extracted from each report.
Discrepancies were resolved by consensus.
Results
In vitro evidence was available in 15 studies. Clinical
evidence of SARS treatment in humans was reported in 54
studies (37 in English, 17 in Chinese). Three studies addressed
treatment of ARDS (Figure 1).
Ribavirin
In vitro. We found six studies that described the antiviral
effect of ribavirin in vitro (Table S4); four showed an antiviral
effect (Table S5). A synergistic antiviral effect between
ribavirin and type I IFN (IFN-b1a or leukocytic IFN-a) was
described in two studies performed in human cell lines and
Vero cell lines [12,13].
In SARS patients. We found 24 studies that described
ribavirin treatment in cohorts larger than ten patients (Table
S6). Our formal assessment classiﬁed 20 studies as ‘‘incon-
clusive,’’ due to study design or because the effect of ribavirin
could not be distinguished from the effects of other treat-
ments (such as steroids and antiviral drugs). Four publications
presented evidence of possible harm (14–17). Three of these
studies, each of which included over 100 patients, documented
a fall in haemoglobin levels after ribavirin treatment when
compared to levels in patients before treatment [14–16]. Of
patients treated with ribavirin, 49/138 to 67/110 (36%–61%)
developed haemolytic anaemia, a recognised complication
with this drug, although it is not possible to rule out the
possibility that SARS-CoV infection caused the haemolytic
anaemia, as there is no control group. One study noted that
over 29% of SARS patients had some degree of liver
dysfunction indicated by ALT levels higher than normal,
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and the number of patients with this complication increased
to over 75% after ribavirin treatment (Table S7) [17].
In the Chinese literature six additional reports described
patients with SARS treated with ribavirin (often with
steroids). These six reports were determined to be incon-
clusive in the evaluation of treatment for SARS (Tables S8
and S9).
LPV/r
In vitro. Of three studies, two demonstrated that lopinavir
inhibits cytopathic effects of SARS-CoV in fetal rhesus
monkey kidney cells (Table S4). One study showed detectable
but reduced activity in Vero-E6 cells [13], and one study
concluded that neither lopinavir nor ritonavir had an effect
[18]. A synergistic effect of lopinavir with ribavirin has been
reported (Table S5).
In SARS patients. We found two studies of LPV/r (lopinavir
400 mg with ritonavir 100 mg orally every 12 h) in cohorts
larger than ten patients (Table S6). Patients also received
ribavirin and corticosteroids. LPV/r use was compared among
three groups of patients: those who received it as an early
SARS treatment, those who received it as a late treatment,
and those who did not receive it at all.
When LPV/r was added as an initial treatment to ribavirin
and corticosteroid therapy, the death rate was lower than
among those who received ribavirin and corticosteroids (1/44
[2.3%] versus 99/634 [15.6%]; p , 0.05) [19]. A second study of
this regimen reported fewer episodes of ARDS or death
compared with historical controls who had not received LPV/
r (1/41 [2.4%] versus 32/111 [28.8%]; p, 0.001) (Table S7) [20].
Both studies were determined to be inconclusive due to
possible bias in the selection of control group or treatment
allocation.
No additional studies were identiﬁed from the Chinese
literature.
Corticosteroids
In vitro. No studies were found on the cytopathic effect of
corticosteroids alone against SARS-CoV. Corticosteroids act
as immunomodulatory agents, and therefore studies to
measure direct antiviral effects in vitro were not expected.
In SARS patients. Fifteen articles examined corticosteroid
treatment in ten or more patients. Of these cohorts 13 were
also treated with ribavirin (Table S6). We determined that 13
of the 15 studies were inconclusive. Of these, in an
uncontrolled and nonrandomised study, 95/107 (89%) of
patients treated with high-dose methylprednisolone (0.5–1
mg/kg prednisolone on day 3 of illness, followed by hydro-
cortisolone 100 mg every 8 h, and pulse-doses of methyl-
prednisolone 0.5 g IV for 3 d) after the ﬁrst week of illness
recovered from progressive lung disease (Table S7) [16].
Two studies contained evidence of possible harm from
corticosteroids [21,22]. One measured SARS-CoV plasma
viral load across time after fever onset in a randomized,
double-blind, placebo-controlled trial; corticosteroid use
within the ﬁrst week of illness was associated with delayed
viral clearance. The other study, which was case-controlled,
found that patients with psychosis received higher cumulative
doses of steroids than patients without psychosis (10,975 mg
versus 6,780 mg; p ¼ 0.017) [22].
In the Chinese literature, we found 14 reports in which
steroids were used (Table S8 and Table S9). Twelve studies
were inconclusive and two showed possible harm. One study
reported diabetes onset associated with methylprednisolone
treatment [23]. Another study (an uncontrolled, retrospective
study of 40 SARS patients) reported avascular necrosis and
osteoporosis among corticosteroid-treated SARS patients [24].
In ARDS patients. Three clinical trials examined the effect
of corticosteroids on mortality in patients with established
ARDS (Table S10). In two trials, high-dose methylpredniso-
lone given for approximately 2 d was not effective for early
ARDS [25,26]. One small RCT that used a regimen of lower
dose methylprednisolone (2 mg/kg per day), tapered after 2
wk, showed possible evidence of ARDS improvement (Table
S11) [27].
IFN Type I
In vitro. Twelve in vitro studies with data on the antiviral
effect of IFN type I have been reported, and all demonstrated
an antiviral effect against SARS-CoV (six for IFN-a and ten
for IFN-b) (Tables S4 and S5). Antiviral effects have been
demonstrated in monkey (Vero; Vero-E6), fetal rhesus
monkey kidney (fRhK-4), and human (Caco2, CL14, and
HPEK) cell lines.
Three reports presented evidence that IFN-b was superior
against SARS-CoV compared to IFN-a and found rIFN-a2
virtually ineffective against SARS-CoV compared to other
IFNs [28]. Synergistic effects were reported for leukocytic
IFN-a with ribavirin [13], IFN-b with ribavirin [12,13] and
IFN-b with IFN-c [28,29].
Box 1. Categories of Evidence Defined for In Vivo Studies of Treatments in SARS Patients
‘‘Inconclusive’’ if a study could not be used to inform a
decision about treatment efficacy due to having either out-
comes which were not reported consistently, an inconsistent
treatment regimen, no control group or a control group which
was a likely source of bias. A control group was considered a
likely source of bias if there were differences in co-morbidities,
sex, age and markers of severe disease compared to the
treatment group.
‘‘Possible harm’’ if a study reported adverse effects of
treatment that were consistent with adverse effects reported
with the use of the drug in the treatment of other conditions.
Evidence of direct causality was not required. A study could be
classified as suggesting possible harm from the drug even if the
study had methodological weaknesses.
‘‘Possible benefit’’ if a study had evidence of benefit for an
important outcome measure which was recorded consistently
(e.g., case fatality, need for mechanical ventilation, duration of
hospitalization, frequency of ARDS) in patients treated in a
defined way compared to a valid control group. A control group
was considered valid if randomized, or if patient characteristics
and illness severity were comparable to the treatment group.
Evidence of direct causality was not required.
‘‘Definite harm’’ if a study contained statistically significant
evidence of harm demonstrated in a double-blind randomized
trial, which did not contain serious methodological weaknesses.
‘‘Definite benefit’’ if a study contained statistically significant
evidence of harm demonstrated in a double-blind randomized
trial, which did not contain serious methodological weaknesses.
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In SARS patients. Two studies of IFN-a given with steroids
and/or ribavirin were reported (Table S6). No signiﬁcant
difference was seen in outcome between IFN-a treatment
group and those treated with other regimens. Results of both
studies were inconclusive due to a lack of a consistent
treatment regimen or suitable control group (Table S7).
In the Chinese literature, one additional study reported the
use of IFN-a as part of a regimen that included ribavirin and
steroids [30]. We determined this study to be inconclusive
because a variety of treatments given masked the effect of
IFN-a alone (Table S8 and Table S9).
Convalescent Plasma or Immunoglobulin
In vitro. No studies were found on the cytopathic effect of
this treatment on SARS-CoV. Convalescent plasma and
IVIG act as immunomodulatory agents and therefore
studies to measure direct antiviral effects in vitro were
not expected.
In SARS patients. Five studies of either IVIG or con-
valescent plasma treatment given in addition to steroids and
ribavirin were reported for treatment of SARS (Table S6).
These studies were inconclusive, because the effect of
convalescent plasma or IVIG could not be discerned from
effects of patient comorbidities, stage of illness, or effect of
other treatments (Table S7).
In the Chinese literature, two additional studies reported
evidence on the effect of convalescent plasma as a treatment
for SARS [30,31]. These studies were inconclusive (Table S8
and Table S9).
Evidence collected on the beneﬁt or harm of drugs used to
treat SARS is summarized in Table 1.
Discussion
The rapid spread and subsequent control of SARS
precluded controlled clinical treatment trials during the
Figure 1. Process of Study Exclusion for Each Objective Category
DOI: 10.1371/journal.pmed.0030343.g001
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outbreak of 2002–2003. In this report we summarize the
results of a systematic evaluation of the ﬁndings from
published reports of treatments used for SARS during the
epidemic. Publications from the Chinese literature were
included to capture as much evidence as possible. We
developed speciﬁc criteria (Box 1) to look for large, obvious
effects of beneﬁt, adverse or poor outcomes, or evidence of
potential beneﬁt that could be used to prioritise future
research of SARS treatments. A summary of this evidence in
SARS patients is shown in Table 1.
Despite thirty reports of SARS-infected patients treated
with ribavirin, there is no convincing evidence that it led to
recovery. Haemolytic anaemia, a recognized side effect of this
treatment, was observed in three studies. We would infer
from these ﬁndings that any future use of ribavirin for SARS
should be within the context of a controlled trial with close
attention given to adverse effects.
Corticosteroids were commonly prescribed to SARS
patients with worsening pulmonary disease or progressing
abnormalities on chest X-rays. Treatment regimens varied
widely but can be classiﬁed into two groups, early treatment
and rescue treatment given at a later stage of illness. It is
difﬁcult to make a clear recommendation about whether
corticosteroids should be used to treat SARS-associated lung
injury in any stage of illness, particularly as the drug is
immunosuppressive and may delay viral clearance if given
before viral replication is controlled [21]. Of added concern
are infectious complications, avascular necrosis, and steroid-
induced psychosis—recognized adverse effects of cortico-
steroid use. Fungal superinfection and aspergillosis have been
noted in case reports and autopsy ﬁndings of SARS patients
given corticosteroids at high doses or for prolonged periods
[32,33]. This review has found evidence of avascular necrosis
and steroid-induced psychosis in SARS patients.
Seven studies of treatment with convalescent plasma or
IVIG, three with IFN type I, and two with LPV/r were
inconclusive by the criteria used in our analyses. Authors of
four of the IVIG studies commented that patients seemed to
improve upon treatment, but that more controlled trials of
this approach are needed to provide evidence of an effect for
SARS.
Important caveats should be considered in this review.
Most of the studies of SARS patients were descriptions of the
natural course of the disease and had not been designed to
reliably assess the effects of the treatments used. Patient
characteristics such as age and presence of diabetes mellitus
have been associated with severe disease and can confound
treatment effects. A diagnostic test for early SARS illness was
not validated or widely available, and in general, treatment
was initiated once patients fulﬁlled a clinical and epidemio-
logical case deﬁnition. It is possible that the inclusion of
patients without laboratory conﬁrmation of SARS-CoV
infection in this review could cause an underestimate of
any true effect of antiviral treatment on SARS.
The variation in treatment regimens—particularly the wide
range in doses, duration of therapy, and route of admin-
istration of ribavirin and corticosteroids—is a major obstacle
to a clear interpretation of the data in this review. The
nonstandardised collection of clinical information limits the
conclusions that can be drawn from a retrospective analysis.
We suggest that, in the event of a future outbreak of SARS-
CoV or another novel agent, attempts be made to develop
treatment protocols and to collect and contribute informa-
tion for a standardized minimum dataset that could facilitate
analysis of treatment outcomes among different settings. As
observational studies pose problems of interpretation, the
need is great for good-quality randomised trials, despite the
difﬁculties in organising such trials.
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Table 1. Summary of the Evidence for Benefit or Harm of Drugs
Used to Treat SARS




Ribavirin 26 4 30
Corticosteroid 25 4 29
LPV/r 2 0 2




aStudies were classified into six categories, but there were four categories without any
studies: ‘‘possible benefit,’’ ‘‘possible harm,’’ ‘‘definite benefit,’’ ‘‘definite harm’’ (see Box 1).
bStudies totalled 54; some reported on more than one drug.
DOI: 10.1371/journal.pmed.0030343.t001
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Editors’ Summary
Background. Severe acute respiratory syndrome (SARS) is caused by a
virus; the main symptoms are pneumonia and fever. The virus is usually
passed on when people sneeze or cough. SARS became a much-talked
about disease in 2003, when over 8,000 cases and 774 deaths occurred
worldwide. The situation was alarming, because the first-ever cases had
only just appeared in 2002, in China, so the best way to treat this new
disease was unknown. Not many drugs are effective against viruses, and
all doctors can usually do with a viral disease is to treat specific
symptoms (e.g., fever and inflammation) and rely on the body’s own
immune system to fight off the virus itself. However, in recent years a
number of antiviral drugs have been developed (for example, several are
in use against HIV/AIDS), so there was hope that some of them might be
active against SARS. Steroids were also often used in SARS treatment to
try to reduce the inflammation of the lungs. In order to find out which, if
any, of the potential treatments for SARS were effective, a number of
research studies were carried out, both during and since the recent
outbreak.
Why Was This Study Done? Health care decisions should be based on
all the information that is available. It is important to try to bring
together all the reliable evidence that exists on each possible treatment
for a disease. The process of doing so is called a systematic review. In
October 2003 the World Health Organization (WHO) established an
International SARS Treatment Study Group, consisting of experts
experienced in treating patients with SARS. The group recommended
a systematic review of potential treatments for SARS. In particular, it was
considered important to summarise the available evidence on the use of
certain antiviral drugs (ribavirin, lopinavir, and ritonavir), steroids, and
proteins called immunoglobulins, which are found naturally in human
blood. The WHO group wanted to know how these treatments affected
the virus outside the body (‘‘in vitro’’) and whether it helped the
condition of patients and reduced the death rate, particularly in those
patients who developed the dangerous complication called acute
respiratory distress syndrome (ARDS). This study is a systematic review
conducted in response to the WHO request.
What Did the Researchers Do and Find? They did no new work with
patients or in the laboratory. Instead they conducted a comprehensive
search of the scientific and medical literature for published studies that
fitted their carefully predefined selection criteria. They found 54 SARS
treatment studies, 15 in vitro studies, and three ARDS studies that met
these criteria. Some of the in vitro studies with the antiviral drugs found
that a particular drug reduced the reproduction rate of the viruses, but
most of the studies of these drugs in patients were inconclusive. Of 29
studies on steroid use, 25 were inconclusive and four found that the
treatment caused possible harm.
What Do These Findings Mean? From the published studies, it is not
possible to say whether any of the treatments used against SARS were
effective. No cases of SARS have been reported since 2004 but it is
always possible that the same or a similar virus might cause outbreaks in
the future. It is disappointing that none of the research on SARS is likely
to be useful in helping to decide on the best treatments to use in such
an outbreak. The authors discuss the weaknesses of the studies they
found and urge that more effective methods of research be applied, in a
timely fashion, in any similar outbreaks in the future. While the
systematic review suggests that we do not know which if any of the
potential treatments against SARS are effective, its recommendations
mean that researchers should at least be better prepared to learn from
potential future outbreaks.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030343.
 Wikipedia entry on SARS (Wikipedia is a free online encyclopedia that
anyone can edit)
 MedlinePlus pages on SARS
 Wikipedia entry on systematic reviews, which includes links to other
Web sites where more detailed information may be found
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